| Name | Title | Contact Details |
|---|
Heart `n Home Hospice & Palliative Care is a local company established on the rural values of hard work and a foundation of integrity. Family owned and operated, Heart `n Home was established in March of 2004 and became Medicare Certified on June 17, 2004. Our core philosophy is to optimize the quality of life for individuals in the final stages of terminal illness. The Heart `n Home ethic and focus of "doing what`s right" has allowed us to flourish and grow to be one of the leading hospice providers in Idaho and Eastern Oregon. This is the epitome of what Heart `n Home is all about. We strive to do what is right for our patients and families; and treasure the privilege of walking people to the gates of eternity. Heart `n Home has over 160 employees and provides hospice and palliative care services to 11 counties in Idaho and Oregon. We have offices in Fruitland (Corporate Headquarters), Caldwell, Emmett, Meridian, Baker City, La Grande, La Pine, and Bend.
Ontario Long Term Care Association is a Markham, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
HSI is a Lombard, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Symbria, we unite passion, insight, and performance to help senior-living and post-acute providers build sustainable success. We don`t make this commitment lightly, understanding full well how challenging this goal is to achieve in today`s demanding, highly competitive environment. Every service we provide – from therapy to pharmacy to wellness to benchmarking – is thoughtfully developed and conscientiously implemented to amplify your ability to effectively and cost-efficiently meet the needs of the residents and patients your community serves.
Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus`. The issued patents` extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.